financetom
Business
financetom
/
Business
/
Soccer-Amorim insists no need to panic in final days of transfer window
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Soccer-Amorim insists no need to panic in final days of transfer window
Feb 2, 2025 9:43 AM

MANCHESTER, England, Feb 2 (Reuters) - Manchester United ( MANU ) manager Ruben Amorim insisted there was no need to panic in the final days of the January transfer window, despite his side slipping to another home defeat on Sunday.

Following their 2-0 defeat to Crystal Palace, United have now lost seven of their first 13 league home matches this season, their joint-most at this stage of a league campaign, along with 1893-94.

Goals have been hard to come by for United, with only Everton and the bottom three finding the net on fewer occasions in the Premier League.

With one day to go until the January window closes, Amorim said there would be no panic in the transfer market.

"We are trying everything to improve the team without doing (the transfer) mistakes of the past," Amorim said. "And trying to balance the urgency of the moment, we know all of the aspects of our club in the moment but we are trying everything.

"When the window closes we will see the players, I'm focused on improving the team as a group, we need to win more games and we will try to do that, this season is like that.

"We need small improvements, try to win points, win the momentum, then we had setbacks and we go again."

Amorim is yet to pick up back-to-back league wins since taking charge in November, but believes the performance against Palace did show signs of improvement.

"The performance improved. Not a lot, but I think we played better than the other games, even against Southampton, we played better today," he added.

"But when you continue to lose, especially at home, you have that feeling it's nothing, the small improvement of the team. Let's go again and see the next game."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ciena's Fiscal Q1 Adjusted Net Income Declines, Revenue Increases; Shares Up Pre-Bell
Ciena's Fiscal Q1 Adjusted Net Income Declines, Revenue Increases; Shares Up Pre-Bell
Mar 11, 2025
07:18 AM EDT, 03/11/2025 (MT Newswires) -- Ciena (CIEN) reported fiscal Q1 adjusted net income Tuesday of $0.64 per diluted share, down from $0.66 a year earlier. Analysts polled by FactSet expected $0.41. Revenue for the quarter ended Feb. 1 was $1.07 billion, compared with $1.04 billion a year earlier. Analysts polled by FactSet expected $1.05 billion. Shares of Ciena...
Korn Ferry Fiscal Q3 Adjusted Earnings Rise, Revenue Falls; Shares Up
Korn Ferry Fiscal Q3 Adjusted Earnings Rise, Revenue Falls; Shares Up
Mar 11, 2025
07:16 AM EDT, 03/11/2025 (MT Newswires) -- Korn Ferry ( KFY ) reported fiscal Q3 adjusted earnings Tuesday of $1.19 per diluted share, up from $1.07 a year earlier. Analysts surveyed by FactSet expected $1.13. Revenue for the quarter ended Jan. 31 was $676.5 million, down from $676.9 million a year earlier. No comparable revenue estimates were available. The company...
Dick's Sporting Goods Fiscal Q4 Non-GAAP Earnings Down, Net Sales Up; Fiscal 2025 Outlook Issued
Dick's Sporting Goods Fiscal Q4 Non-GAAP Earnings Down, Net Sales Up; Fiscal 2025 Outlook Issued
Mar 11, 2025
07:20 AM EDT, 03/11/2025 (MT Newswires) -- Dick's Sporting Goods (DKS) reported fiscal Q4 non-GAAP earnings Tuesday of $3.62 per diluted share, down from $3.85 a year earlier. Analysts polled by FactSet expected $3.52. Net sales for the fiscal quarter ended Feb. 1 were $3.89 billion, up from $3.88 billion a year earlier. Analysts surveyed by FactSet expected $3.78 billion....
Legend Biotech's Q4 Net Loss Narrows, Revenue Rises
Legend Biotech's Q4 Net Loss Narrows, Revenue Rises
Mar 11, 2025
07:16 AM EDT, 03/11/2025 (MT Newswires) -- Legend Biotech ( LEGN ) reported Tuesday a Q4 adjusted net loss of $0.15 per diluted share, narrower than its loss of $0.24 per share a year earlier. Analysts polled by FactSet expected a loss of $0.25. Revenue for the quarter ended Dec. 31 was $186.5 million, up from $79.5 million a year...
Copyright 2023-2025 - www.financetom.com All Rights Reserved